Drugmaker Johnson & Johnson has halted manufacturing of its single-dose COVID-19 vaccine, in response to a New York Instances report.
The pharmaceutical firm final 12 months quietly shut down manufacturing at a plant in Leiden, Netherlands, which was the one facility the place usable doses of the vaccine had been manufactured, catching a few of its clients off guard, together with growing nations that want the single-dose J&J drug over two-dose options, the report states.
Johnson & Johnson has as an alternative been utilizing the plant to work on an experimental and probably extra worthwhile drug that would shield in opposition to an unrelated respiratory virus, in response to the report.
The plant is anticipated to renew manufacturing of the COVID-19 vaccine, however it’s unclear when.
J&J didn’t touch upon the plant closure experiences, however mentioned in a press release to CBS Information “we presently have tens of millions of doses of our COVID-19 vaccine in stock” and “we proceed to satisfy our contractual obligations … [to] the African Union.”
Vaccine of selection for poorer nations
The J&J vaccine, known as the Janssen COVID-19 vaccine, made by Janssen Biotech, a subsidiary of Johnson & Johnson, is the vaccine of selection for poorer nations which are relying on the drugmaker to assist them struggle the pandemic.
Wealthier nations just like the U.S. have favored pictures from Moderna and Pfizer, as a result of the 2 seem like more practical in opposition to COVID-19 variants like Omicron, and since the Janssen vaccine has, up to now, been linked to uncommon however probably life-threatening blood clots.
Provided that just one dose of the J&J vaccine is required, although, it is inexpensive than its double-dose counterparts and likewise simpler to ship, making it fashionable in lower-income nations.